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Abstract 
Background: Duration of dual antiplatelet therapy (DAPT) following drug-eluting stents 
(DES) remains controversial and is a topic of ongoing research. 
Methods: Direct and adjusted indirect comparisons of all the recent randomized control trials 
(RCTs) were performed to evaluate the safety of short-term versus long-term DAPT 
following DES. 
Results: 8 RCTs were identified and 7 (16 318 subjects) were included. 4 groups of 3 vs 12 
months, 6 vs 12 months, 6 vs 24 months and 12 vs 24 months of DAPT were used for direct 
comparison. There was no significant difference in stent thrombosis, myocardial infarction 
(MI), stroke and revascularization, cardiovascular and all-cause mortality between the 
different durations in all 4 groups. Pooling trials of 3 - 6 months of DAPT against 12 months, 
we found a significant reduction in the risk of total bleeding (RR 0.61, 95% CI 0.43 – 0.87). 
Adjusted indirect comparison between 3 vs 6 months, 3 vs 24 months and 6 vs 24 months 
duration of DAPT showed no significant differences in risk of death or MI, or 
revascularization between 3 or 6 months and 24 months. However, 24 months of DAPT was 
associated with significantly more bleeding than 3 or 6 months.   
Conclusions: 3 to 6 months of DAPT following second generation DES and above is safe 
with no increased risk of thrombotic complications and mortality and lower bleeding risk. 
However a tailored approach may be more appropriate for high-risk patients. 
Key words: Percutaneous coronary intervention; drug-eluting stent; acute coronary 
syndrome; dual antiplatelet treatment; duration of therapy 
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Introduction 
 
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is the mainstay 
treatment after drug-eluting stent (DES) implantation and has been shown to reduce stent 
thrombosis1-3. However, with the emergence of newer generation DES, late and very late 
stent thrombosis have reduced significantly4. Prolonged treatment with DAPT is associated 
with a higher bleeding risk5-7, can be costly and can delay elective and semi-elective 
operations. Therefore, the optimal duration of DAPT after DES remains a topic of ongoing 
debate and research.  
 
North American and European recommendations differ and are largely based on 
observational studies1, 8, 9. The American Heart Association (AHA)/American College of 
Cardiology (ACC) recommend at least 12 months of aspirin and clopidogrel after DES 
implantation for patients at low risk of bleeding 10 whereas the European Society of 
Cardiology (ESC) recommends 6 to 12 months of DAPT for patients following elective DES 
implantation and 12 months in the context of acute coronary syndromes11 .  
 
We recently published a meta-analysis 12 on 4 RCTs and found no cardiovascular or mortality 
benefits associated with prolonged duration of DAPT. Moreover, shorter periods of DAPT 
resulted in a lower risk of major bleeding as compared to longer periods. At that time, we 
noted that there were a number of other ongoing trials, and we have now become aware of 
recent RCTs13-16 published on this topic. The availability of additional new trial data in an up-
to-date meta-analysis would help us overcome previous limitations of lack of power and 
generalizability, and also enable us to conduct an adjusted indirect comparison between 
treatment durations that had not been directly compared in existing trials.
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Methods 
Eligibility criteria 
RCTs comparing different durations of dual antiplatelet therapy (aspirin plus any one of the 
P2Y12 inhibitors: ticlopidine, clopidogrel, prasugrel and ticagrelor) following percutaneous 
coronary intervention (PCI) were included. We focused on RCTs using only DES or a 
mixture of predominantly DES and some bare metal stents (BMS). Trials comparing different 
stents, or different antiplatelet agents rather than different durations of DAPT after PCI were 
excluded. 
 
Search strategy 
MEDLINE and EMBASE through OvidSP using the Haynes optimized search strategy 
(Health Information Research Unit, McMaster University) 17 were searched. Conference 
Proceedings (from August 2013 to October 2014) of the AHA, ACC, ESC and the 
Transcatheter Cardiovascular Therapeutics (TCT) were searched manually. The exact search 
strategy is shown in Appendix 1. We also checked the references of included RCTs for any 
relevant studies. In addition, we used the PubMed automated updates for new articles up to 
October 2014. 
 
Study selection and data abstraction 
Two reviewers (HB and CSK) independently and in duplicate assessed trial eligibility based 
on titles and abstracts. The reviewers then went on to screen the full-text articles of 
potentially suitable RCTs for detailed evaluation against the eligibility criteria. 
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Following discussion and full agreement, the two reviewers independently extracted data 
from the selected studies. The data extraction was then checked by the other authors (YKL 
and ADR) and any discrepancies were resolved by consensus. 
 
We evaluated individual endpoints of myocardial infarction, stroke, cardiovascular death, all-
cause mortality, stent thrombosis and need for revascularization. In addition, we considered a 
composite endpoint of death or myocardial infarction to be of clinical relevance within our 
analysis. 
 
We aimed to evaluate adverse events including total number of bleeds, major bleeding, as 
well as specific subcategories of gastrointestinal bleeding and intracranial hemorrhage where 
reported. 
 
Study characteristics and quality assessment 
As reported in our previous meta-analysis 12, two reviewers (HB and CSK) extracted data on 
study characteristics, which was then checked by the other reviewers (AR and YKL). We 
recorded the study design, duration of DAPT exposure, number of participants, duration of 
follow up, outcomes evaluated, outcome events, PCI procedural data, angiogram results, 
patient selection criteria, compliance with medication and doses of antiplatelet used in the 
RCTs. 
 
Quality assessment was conducted based on the recommendations of the Cochrane handbook 
of systematic reviews 18 which included consideration of randomization sequence generation, 
allocation concealment, blinding of participants, personnel and outcome, incomplete or 
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selective outcome reporting and publication bias. We aimed to produce a funnel plot if there 
were >10 included studies with no evidence of statistical heterogeneity. 
 
Quantitative data synthesis 
RevMan 5.2 (Nordic Cochrane Center) was used to conduct fixed-effect meta-analysis for the 
pooled Relative Risks (RR), with 95% confidence intervals for dichotomous outcomes. The 
main analysis was on an intention to treat basis, and all reported P values are two-sided, with 
significance set at p less than 0.05. Statistical heterogeneity was assessed using I2 statistic, 
with I2 values of 30-60% representing a moderate level of heterogeneity 19. 
 
We aimed to perform pre-specified subgroup analysis based on nature and duration of 
antiplatelet therapy, type of stent, and on specific patient populations such as the elderly, or 
those with diabetes mellitus. Risk ratios were pooled using the inverse variance method for 
specific patient subgroups in the trials. 
 
Adjusted Indirect Comparison 
We used the summary estimates of treatment effect from the meta-analysis in adjusted 
indirect comparison (AIC) (Bucher’s method20) through ITC software21. The AIC technique 
compares the size of the treatment effect between two treatment regimens judged in relation 
to a common comparator, which works as a link between the two regimens. A large survey 
has demonstrated that AIC can yield effect estimates similar to those derived from direct or 
head-to-head trials22. At present, AIC is considered to be the most established method for 
indirect comparisons, with acceptance by pharmaceutical reimbursement agencies such as 
Australian Pharmaceutical Benefits Advisory Committee, the UK National Institute for 
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Health and Clinical Excellence, and the Canadian Agency for Drug and Technologies in 
Health23.  
Here, the treatment effects from two different antiplatelet regimens could be compared 
indirectly through a common control DAPT duration. For instance, if the outcomes data were 
available for 3 months vs. 12 months DAPT, and 6 months vs. 12 months DAPT, we aimed 
to compare 3 months vs. 6 months through AIC based on the 12 months common control 
arm. In order to check the validity of the AIC, we aimed to evaluate the results obtained 
through AIC against that of any head-to-head data where available. 
 
Results 
Study selection, design and methodology 
Our previous search up to August 2013 yielded 20 potentially relevant studies and a total of 5 
were included in our recent study12.  From August 2013 to October 2014 3 new studies were 
identified via MEDLINE and EMBASE through OvidSP. The article by Lee et al 14 actually 
consists of two trials as it included all the participants from REAL-LATE and ZEST-LATE 
previously published by Park et al 24 and therefore the latter was excluded from our analysis. 
The process of study selection is shown in Appendix 1.  The study design, definition of short 
and long duration of therapy, number of participants, follow-up time and outcomes evaluated 
is shown in Table 1.  The duration of short- and long-term antiplatelet therapy varied from 3 
months to 12 months for the short duration and 12 to 24 months for the long duration.  The 
number of participants ranged from 182 to 3,119 with a total of 16,534 participants across all 
eight studies.  The follow up time for outcome evaluation ranged from 1 year to 3 years after 
PCI.  The studies evaluated composite cardiovascular events and mortality as their primary 
outcome and secondary individual cardiovascular events and mortality outcomes.  The 
participant selection criteria, patient demographics, clinical presentation, procedural 
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information for PCI, angiography results, study outcomes, compliance with medications are 
shown in Appendix Table 2-6. 
 
Quality assessment 
The quality of studies is shown in Appendix 7. Randomization was considered adequate for 
six out of eight trials, but some degree of loss to follow up was noted in the same six trials. 
Although the majority of the studies were open-label, blinded observers independently 
adjudicated the adverse events in five of them. We did not test for publication bias as there 
were too few trials. 
Pooled analysis of thrombotic events for shorter as compared to longer duration of DAPT 
The number of thrombotic events in the shorter and longer duration of DAPT is shown in 
Appendix 8. A total of seven articles (reporting on eight trials) were included which 
evaluated 3 vs 12 months, 6 vs 12 months, 6 vs 24 months and 12 vs 24 months and there 
was no significant difference in stent thrombosis, myocardial infarction, stroke and 
revascularization with shorter or longer duration of DAPT (Figure 1).   
 
Pooled analysis of mortality events for shorter as compared to longer duration of DAPT 
The composite of death or myocardial infarction was available from all the included trials and 
similarly there was no significant difference with shorter and longer duration of DAPT 
(Figure 2).  For all-cause mortality, meta-analysis of all the included trials showed a non-
significant trend towards slightly less events with shorter duration of DAPT (Figure 2). 
 
Pooled analysis of risk of bleeding for shorter as compared to longer duration of DAPT 
All the studies were included in the analysis of major bleeding (Appendix 9, Figure 3).  For 
the four different time comparisons (3 vs 12 months, 6 vs 12 months , 6 vs 24 months and 12 
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vs 24 months) there was a non-significant trend towards fewer bleeding events with 3 vs 12 
months, 6 vs 12 months and 12 vs 24 months and significantly fewer events with 6 vs 24 
months (RR 0.38, 95% CI 0.15-0.96).  For total bleeding, significant differences in events 
was observed for 12 vs 24 months (RR 0.25, 95% CI 0.07-0.90), but no significant difference 
was observed for the comparison of 3 vs 12 months (RR 0.72, 95% CI 0.48-1.08), 6 vs 12 
months (RR 0.42, 95% CI 0.15-1.19) and 6 vs 24 months (RR 0.56, 95% CI 0.30-1.04) 
(Figure 3).  
 
Risk of adverse outcomes with specified subgroup with continued and discontinued 
antiplatelet therapy 
We considered different categories of participants as an additional analysis (Figure 4).  There 
was no significant difference with shorter and longer duration of DAPT for the subgroups of 
age <65-years/ age> 65 years, diabetes/no diabetes and acute coronary syndrome/ stable 
disease. 
 
One study by Hu et al 25 was not included in the pooled analysis due to insufficient 
information for detailed quantitative analysis but its findings are consistent with our meta-
analysis. This trial randomized 182 Chinese patients who were event-free at 12 months post 
left main stem PCI to 12 months or ≥36 months of dual antiplatelet therapy and found that 
there was no difference between the groups for mortality, myocardial infarction, stent 
thrombosis or composite outcomes. 
 
Adjusted Indirect Comparison of different treatment durations 
In order to maximize statistical power in the AIC, we chose outcomes that were reported 
most frequently in the entire dataset of all eight trials i.e. death or MI, revascularization, and 
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major bleeding. Results for the AIC are shown in Table 2. There were no significant 
differences in risk of death or MI, or revascularization when comparing patients receiving 3 
or 6 months DAPT to those treated for 24 months. However, 24 months of DAPT was 
associated with a significant excess of major bleeding compared to 3 or 6 months.  We did 
not identify significant differences when comparing 3 months DAPT to 6 months DAPT for 
any of the outcomes. 
We were able to check the validity of the AIC estimate (for 6 vs. 24 months) by evaluating it 
against Valgimigli’s trial involving a direct head-to-head comparison of 6 months vs. 24 
months. For Death or MI, the adjusted indirect estimate of RR 1.12 (95% CI 0.62 – 2.03) was 
very similar to that seen in the direct comparison RR 1.07 (95% CI 0.81 – 1.41). The analysis 
of major bleeding for 6 vs. 24 months showed an adjusted indirect RR of 0.32 (95% CI 0.11-
0.98), which again was very similar to the direct RR estimate of 0.38 (95% CI 0.15 – 0.96) 
from Valgimigli’s trial26. 
 
Evaluation of 3 or 6 months against longer durations 
As part of a sensitivity analysis, we also pooled the data from the 3 month and 6 month trials 
to enable a comparison of 3 to 6 months versus 12 months. This showed no significant 
difference between the two aforementioned durations with regards to death/MI (RR 1.06, 
95% CI 0.82 – 1.38), or revascularization (RR 1.12, 95% CI 0.89 – 1.42), but a significant 
reduction in risk of total bleeds (RR 0.61, 95% CI 0.43 – 0.87) and a non-significant 
reduction in major bleeds (RR 0.57, 95% CI 0.32 – 1.01).  
We also conducted a sensitivity analysis involving pooled estimates from the three trials 
where 6 months duration was compared to 12-24 months. This showed no significant 
difference between the shorter and longer duration with regards to death /MI (RR 1.08, 95% 
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CI 0.85 – 1.37), but the 6 months arm was associated with significant reductions in risk of 
major bleeds (RR 0.44, 95% CI 0.22 – 0.86) and total bleeds (RR 0.52, 95% CI 0.30 – 0.88). 
 
Discussion 
DES is currently the stent of choice in patients undergoing PCI due to its lower risk of 
restenosis and target lesion revascularization27. However, this is offset by the risk of late and 
very late stent thrombosis. Although stent thrombosis is becoming less frequent with newer 
generation DES4, 28, 29, mortality can be as high as 45%1. On the other hand, DAPT has been 
shown to significantly increase the risk of bleeding5-7. Therefore it is important to prescribe 
the optimal duration of DAPTs to patients to balance their thrombotic and hemorrhagic risks. 
Our up-to-date analysis of randomized data of 16 318 participants demonstrates that 
extending the period of DAPT does not significantly reduce the risk of thrombotic 
complications and mortality when compared to shorter durations but the risk of bleeding is 
clearly increased when compared with shorter duration DAPT. Overall 3-6 months of DAPT 
is associated with the lowest risk of harm from bleeding, with direct supporting evidence 
from the pooled comparison of 3-6 months vs. 12 months, and 6 months vs. 12-24 months, as 
well as adjusted indirect evidence of 3-6 months vs. 24 months treatment. This was mainly 
driven by significantly less bleeding with shorter duration treatment and there was no added 
benefit from death or MI and revascularization when treatment was extended to 24 months. 
 
The absence of cardiovascular harm with shorter durations of DAPT was consistently noted 
in different subgroups stratified by duration of DAPT, individual endpoints, or patient   
characteristics. Although Gwon et al 30 suggested that patients with diabetes mellitus were at 
significantly higher risk of myocardial infarction and target vessel revascularization in the 
short DAPT group, this was not the case with OPTIMIZE 13 and our subgroup analysis did 
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not demonstrate any impact of age, presence of diabetes mellitus and acute coronary 
syndrome (ACS) on the adverse primary outcomes in both short and long DAPT groups. Our 
results build upon the findings of our previous meta-analysis 12 but with a much larger sample 
size and stronger statistical power overall and provide the strongest evidence to date on this 
topic.  Shorter duration of DAPT seems a safe option; especially in low risk patients having 
second generation stents but the cohort of patients that would benefit from longer duration of 
DAPT remains unanswered.  
 
Late stent thrombosis is thought to be the result of delayed arterial healing after DES 31 and 
can be due to a combination of various factors such as comorbidities of the patient and lesion-
specific and stent-specific characteristics 32. However, premature DAPT cessation is 
considered to be the main cause of stent thrombosis1. Therefore it is likely that we would 
never find a simple answer for the optimal duration of DAPT that would apply to all patients. 
This is also compounded by the fact that newer stents are constantly being designed and 
newer antiplatelet agents are increasingly being used in clinical practice. These make the 
conduct of a large-scale RCT that could potential stratify for all confounding factors very 
difficult and the result of such a trial may become obsolete once it is finally published 
because of the constant evolution in technology and pharmacology. Therefore, in an attempt 
to update the current evidence on this topic, there have been a number of meta-analyses12, 26, 
33-35 conducted over the last few years. Our meta-analysis, to our knowledge, is the most up-
to-date and summarizes all the relevant RCTs to date. 
 
Our study has several strengths. First of all we included high quality RCTs only, totaling > 
16000 patients, which has more power that previous meta-analyses of RCTs only conducted 
on this topic 12, 26, 34, 35. Secondly, our previous work 12 had patients from South Korea and 
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Italy only but now includes more patients from Europe and includes patients from the South 
American continent. The current work also includes a proportion of patients on prasugrel 
(8.5% of patients in the ARTIC-INTERRUPTION trial), which is being used more frequently 
in clinical practice and may be more representative.  
 
However, our study also has several limitations. First of all, the RCTs included were 
comparing different durations of DAPT, which made pooling of the different time points 
difficult. We had to conduct an adjusted indirect comparison of durations of DAPT not 
directly compared in the RCTs, but our consistency check was reassuring in that the AIC for 
6 vs. 24 months yielded very similar findings to the direct comparison. Secondly, the time of 
randomization differed in these 7 studies with randomization performed at index PCI in 
EXCELLENT 30, RESET 36, OPTIMIZE 13 and SECURITY 16 trials and at 1 month after 
index PCI in PRODIGY 37. In the study by Lee et al 14 and ARTIC-INTERRUPTION 15, 
randomization was performed at a year post the index PCI. As a result, patients developing 
early adverse events (within 30 days and within 12 months respectively) in the later 3 studies 
were excluded. Therefore it was not possible to analyze events within 30 days and within 12 
months in these patients. The SECURITY trial did reported on numbers of cardiovascular 
events at different time-points of follow-up and no consistent differences were reported. 
EXCELLENT 30, RESET 36 and OPTIMIZE 13 trials provided Kaplan-Meier plots, which 
individually did not show significant differences in cardiovascular outcomes during follow-
up. Furthermore, in the former 3 studies, EXCELLENT 30 excluded patients with myocardial 
infarction within 72 hours, RESET 36 and SECURITY 16 excluded patients with acute ST-
elevation myocardial infarction within 48 hours and OPTIMIZE 13 also excluded patients 
with acute ST-elevation myocardial infarction. PRODIGY 37 on the other hand included 
patients with acute coronary syndrome including non ST-elevation and ST-elevation 
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myocardial infarction, which accounted for around 74% of patients. Lastly, different 
generations of DES and a small proportion of BMS (25% of patients in PRODIGY37) were 
used in the trials included in this analysis. Although the majority of the trials used second-
generation stents (61% in SECURITY, 63% in ARCTIC-INTERRUPTION, 75% in 
EXCELLENT, 86 % in RESET, 100% in OPTIMIZE) except in Lee et al (30%) and 
PRODIGY (50%), we were not able to extract the required data to perform a sensitivity 
analysis pertaining to the stent type. The Endeavor Zotarolimus-Eluting Stent (ZES) used in 
RESET 36 in 50% of the cohort and in the OPTIMIZE 13 has now been superseded by the 
Resolute ZES which has a new durable polymer coating with improved drug-release kinetics. 
However, in this rapidly evolving field, it is inevitable that the stent platform with continue to 
change in the current ongoing and future trials. 
A retrospective study by Silber et al 38 recently found that patients with the Resolute ZES 
who interrupted DAPT after at least one month was safe which supports the notion that 3 
months of DAPT following DES with the newer generation DES in low risk patients is safe. 
On the other hand, a recent meta-analysis of almost 50,000 patients by D’Ascenzo et al 39 
showed that ACS patients undergoing PCI suffered more adverse events compared to ACS 
patients treated medically if they stopped DAPT after a year. Although they concluded that 
this result was hypothesis generating, it supports the fact that high-risk patients would need a 
tailored approach to the duration of DAPT. 
 
 Several other RCTs on this topic are currently being undertaken (DAPT trial 40, ISAR-SAFE 
41, OPTIDUAL 42, Nobori DAPT (NCT01514227), EDUCATE (NCT01069003), DAPT-
STEMI (NCT01459627), SMART-DATE (NCT1701453)). All of these trials are comparing 
between 6 to 12 months of DAPT against 12 to 30 months and looking at different clinical 
presentations and stent platforms. Therefore it is likely that we would be able to identify 
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patients who would benefit from longer duration of DAPT in a near future. GLOBAL 
LEADERS (NCT01813435) is the largest RCT involving DES designed so far, aiming to 
recruit 16 000 participants. This trial is currently looking at all-comers post PCI (Biomatrix 
FlexTM: DES and an abluminally coated biodegradable polymer) on DAPT with aspirin and 
ticagrelor for one month, then randomized to either ticagrelor monotherapy for 23 months or 
standard therapy (12 months of either clopidogrel or ticagrelor with aspirin) and so we would 
have more data on ticagrelor use post PCI. 
 
Conclusions 
3 to 6 months of DAPT following second generation DES and above is safe with no increased 
risk of stent thrombosis, myocardial infarction, stroke, revascularization and death and the 
added benefit of minimizing the risk of bleeding. A tailored approach may be appropriate for 
high-risk patients.  
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